Absence of Common Somatic Alterations in Genes on 1p and 19q in Oligodendrogliomas
暂无分享,去创建一个
Andrew P. Stubbs | C. Hoogenraad | M. Moorhouse | P. J. van der Spek | P. French | J. Kros | P. S. Sillevis Smitt | C. Kockx | A. Stubbs | L. Bralten | Lale Erdem | W. V. van Ijcken | S. Nouwens
[1] C. Hoogenraad,et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo , 2011, Annals of neurology.
[2] S. Mane,et al. K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension , 2011, Science.
[3] Zev A. Binder,et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.
[4] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[5] M. J. van den Bent,et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? , 2011, The Lancet. Oncology.
[6] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[7] C. Hoogenraad,et al. Integrated genomic profiling identifies candidate genes implicated in glioma‐genesis and a novel LEO1‐SLC12A1 fusion gene , 2010, Genes, chromosomes & cancer.
[8] C. Hoogenraad,et al. Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma , 2010, Human mutation.
[9] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[10] Andrew P. Stubbs,et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.
[11] H. Kitchener,et al. Analogues of Y27632 increase gap junction communication and suppress the formation of transformed NIH3T3 colonies , 2009, British Journal of Cancer.
[12] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.
[13] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[14] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[15] G. Reifenberger,et al. Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss , 2008, International journal of cancer.
[16] A. Mills,et al. The quest for the 1p36 tumor suppressor. , 2008, Cancer research.
[17] A. Joe,et al. Oncogene addiction. , 2008, Cancer research.
[18] M. J. van den Bent,et al. Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. , 2007, Cancer research.
[19] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[20] H. Vogel,et al. CHD5 Is a Tumor Suppressor at Human 1p36 , 2007, Cell.
[21] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[22] G. Reifenberger,et al. Identification of novel oligodendroglioma‐associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray‐based expression profiling , 2006, International journal of cancer.
[23] 司履生. Cancer epigenetics , 2006 .
[24] Jord H A Nagel,et al. Gene expression profiles associated with treatment response in oligodendrogliomas. , 2005, Cancer research.
[25] S. Batzoglou,et al. Distribution and intensity of constraint in mammalian genomic sequence. , 2005, Genome research.
[26] P. Kleihues,et al. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.
[27] Miguel Alaminos,et al. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. , 2005, Cancer research.
[28] Marc Ladanyi,et al. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] P. Laird. Cancer epigenetics. , 2005, Human molecular genetics.
[30] R. McLendon,et al. Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.
[31] D. Horsman,et al. Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity , 2003, Journal of Neuro-Oncology.
[32] J. Menten,et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. J. van den Bent,et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.
[34] Galina Selivanova,et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.
[35] Takaaki Kirino,et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] D. Louis,et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.
[37] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.